FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Maurie Markman

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Occupations

Medical Oncology

Co-author Network

Publications

TOP 3
Maurie Markman
Provider impact on survival outcomes in the management of malignant disease.
Digant Gupta; Donald P Braun; Edgar D Staren; Maurie Markman
Longitudinal health-related quality of life assessment: implications for prognosis in ovarian cancer.
Eiko Klimant; Maurie Markman; Daniela M Albu
Clinically meaningful responses to sequential gemcitabine-based chemotherapy regimens in a patient with metastatic pancreatic cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Maurie Markman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Maurie Markman
Provider impact on survival outcomes in the management of malignant disease.
Current oncology reports 2013;15(3):193-6.
2013: Digant Gupta; Donald P Braun; Edgar D Staren; Maurie Markman
Longitudinal health-related quality of life assessment: implications for prognosis in ovarian cancer.
Journal of ovarian research 2013;6(1):17.
2013: Eiko Klimant; Maurie Markman; Daniela M Albu
Clinically meaningful responses to sequential gemcitabine-based chemotherapy regimens in a patient with metastatic pancreatic cancer.
Case reports in oncology 2013;6(1):72-7.
2013: Maurie Markman
Chemoradiation in the management of cervix cancer: current status and future directions.
Oncology 2013;84(4):246-50.
2013: Maurie Markman
Optimizing the use of oral anti-neoplastic drug therapy.
Oncology 2013;84(2):65-6.
2013: Maurie Markman
Risk of cervical cancer after HPV vaccination.
Current pharmaceutical design 2013;19(8):1488-9.
2012: Maurie Markman
Precision medicine and the rapidly approaching future of cancer management.
The American journal of managed care 2012;18(5 Spec No.):SP207-8, cover.
2012: Maurie Markman
Abandoning "TAP" as treatment of metastatic endometrial cancer: a serious example of the consequences resulting from the failure to adequately define the question being addressed in a phase 3 trial.
Current oncology reports 2012;14(6):480-2.
2012: David A Litvak; Salman Malad; Maurie Markman; Robert A Wascher; Jiaxin Niu
Laparoscopic Splenectomy in Colorectal Cancer Patients with Chemotherapy-Associated Thrombocytopenia due to Hypersplenism.
Case reports in oncology 2012;5(3):601-7.
2012: Curt Heese; Pablo Lavagnini; Mark Lewis; Pamela Mills; Maurie Markman
Superficial Hyperthermia plus External Beam Radiation in the Palliation of Locally Progressive Chemoradiation-Resistant Breast Cancer.
Case reports in oncology 2012;5(3):520-3.
2012: Siqing Fu; David M Gershenson; Bryan T Hennessy; Adrienne Howard; Ed Jackson; Zhenlin Ju; John J Kavanagh; Vikas Kundra; Razelle Kurzrock; Charles F Levenback; Jane Li; Yang Li; Maurie Markman; Edward Atkinson; Robert C Bast; Robert L Coleman; Kevin R Coombes; Kristine Dice; Mary Dyer; Chaan S Ng; Anil K Sood; Katherine Stemke-Hale; Judith K Wolf; Gordon B Mills
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Gynecologic oncology 2012;126(1):47-53.
2012: Maurie Markman
Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.
Gynecologic oncology 2012;125(1):278; author reply 278-9.
2012: Maurie Markman
Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward.
Nature reviews. Clinical oncology 2012;9(2):69-70.
2012: Ginger J Gardner; Maurie Markman; David Spriggs; Raymond E Baser; Mark F Brady; Robert E Bristow; Howard T Thaler
CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.
Gynecologic oncology 2012;124(2):216-20.
2012: Digant Gupta; Maurie Markman; Mark Rodeghier; Christopher G Lis
The relationship between patient satisfaction with service quality and survival in pancreatic cancer.
Patient preference and adherence 2012;6():765-72.
2012: Maurie Markman
Retrospective analyses of cancer trials or existing clinical databases: potential for highly clinically relevant hypothesis generation.
Oncology 2012;83(6):329-30.
2012: Maurie Markman
Palliation of symptomatic malignant ascites: an (often) unmet need.
Oncology 2012;82(6):313-4.
2012: Christopher G Lis; Maurie Markman; Digant Gupta; Carolyn A Lammersfeld; Pinaki Vashi
Role of nutritional status in predicting quality of life outcomes in cancer--a systematic review of the epidemiological literature.
Nutrition journal 2012;11():27.
2012: Maurie Markman
The promise and perils of measuring circulating tumor cells.
Oncology 2012;82(1):1-2.
2011: Angeles Alvarez-Secord; Kathleen M Darcy; Laura Havrilesky; Zhiqing Huang; Alan Hutson; Elizabeth Jewell; Paula S Lee; Maurie Markman; Franco Muggia; Susan Murphy
The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.
Gynecologic oncology 2011;123(2):314-9.
2011: Maurie Markman
Involvement of bone in epithelial ovarian cancer: case report of an uncommon late metastatic event.
Case reports in oncology 2011;4(3):490-1.
2011: Chad A Hamilton; Thomas Krivak; Maurie Markman; Austin Miller; Caela Miller; Robert F Ozols; G Scott Rose; Michael P Stany; Deborah K Armstrong; Mildred R Chernofsky; John H Farley; G Larry Maxwell
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.
Gynecologic oncology 2011;122(3):521-6.
2011: Jamie L Lesnock; Coreen Farris; Thomas Krivak; Kenneth J Smith; Maurie Markman
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
Gynecologic oncology 2011;122(3):473-8.
2011: Maurie Markman
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimes: a phase II study of the Gynecologic Oncology Group.
Gynecologic oncology 2011;122(2):462; author reply 462-3.
2011: Maurie Markman
Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown.
Gynecologic oncology 2011;122(2):213-4.
2011: Maurie Markman
Information overload in oncology practice and its potential negative impact on the delivery of optimal patient care.
Current oncology reports 2011;13(4):249-51.
2011: Maurie Markman
Role of chemotherapy in epithelial ovarian cancer.
Minerva ginecologica 2011;63(3):287-97.
2011: Roshni Kalachand; Bryan T Hennessy; Maurie Markman
Molecular targeted therapy in ovarian cancer: what is on the horizon?
Drugs 2011;71(8):947-67.
2011: Eiko Klimant; Daniela M Albu; Maurie Markman
Synchronous presentation of a primary iliac lymph node plasmacytoma and a prostate adenocarcinoma.
Case reports in oncology 2011;4(2):311-4.
2011: Tate Thigpen; Monica Bacon; Jonathan Berek; Nicoletta Colombo; Philip DiSaia; Andreas duBois; Gilles Freyer; Keiichi Fujiwara; Dolores Gallardo; William Hoskins; Henry Kitchener; Gunnar Kristensen; Robert Mannel; Maurie Markman; Jessica McAlpine; Jacobus Pfisterer; Marie Plante; Andres Poveda; Michael Quinn; Nick Reed; Lawrence Rubinstein; Gavin C E Stuart; Ann Marie Swart
First-line therapy in ovarian cancer trials.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011;21(4):756-62.
2011: Lisa N Abaid; Bram H Goldstein; Katrina L Lopez; John P Micha; John V Brown; Mark A Rettenmaier; Maurie Markman
The prognostic significance of optimal debulking in the setting of a complete clinical response for advanced ovarian carcinoma patients receiving maintenance chemotherapy.
Archives of gynecology and obstetrics 2011;283(5):1127-31.
2011: Siqing Fu; Wei Hu; Revathy Iyer; John J Kavanagh; Robert L Coleman; Charles F Levenback; Anil K Sood; Judith K Wolf; David M Gershenson; Maurie Markman; Bryan T Hennessy; Razelle Kurzrock; Robert C Bast
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Cancer 2011;117(8):1661-9.
2011: Maurie Markman
Commentary: Implications of cancer managed as a "chronic illness".
Current oncology reports 2011;13(2):90-1.
2011: Brian M Slomovitz; Michael J Worley; Maurie Markman; Robert L Coleman
Emerging therapeutics for primary peritoneal cancer.
Expert opinion on emerging drugs 2011;16(1):71-84.
2011: Maurie Markman
The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapy.
Cancer 2011;117(4):660-1.
2011: Maurie Markman
Patterns of care studies in oncology: considerable potential utility, but risk of serious bias.
Oncology 2011;81(3-4):158-9.
2011: Maurie Markman
Outcomes when cancer treatment is delivered on, or off, a clinical trial: implications for generalizability of study results.
Oncology 2011;81(3-4):141-2.
2011: Maurie Markman
Evidence for ethnic differences in cancer drug metabolism and deposition: potential relevance for clinical trials and practice.
Oncology 2011;81(2):63-4.
2011: Maurie Markman
Use of predictive markers in oncology: are phase 3 trials always required?
Oncology 2011;81(1):1-2.
2011: Maurie Markman
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer.
Cancer management and research 2011;3():219-25.
2011: Maurie Markman
Cross-trial comparisons in the oncology arena: when is this justified?
Oncology 2011;80(3-4):151-2.
2011: Rachna Anand; Maurie Markman
Elevated Serum CA-125 in a Patient with Follicular Lymphoma and a History of Ovarian Cancer.
Case reports in oncology 2011;4(1):172-4.
2011: Maurie Markman
Counterpoint: chemosensitivity assays for recurrent ovarian cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(1):121-4.
2010: Mark G Kris; Steven I Benowitz; Sylvia Adams; Lisa Diller; Patricia Ganz; Morton Kahlenberg; Quynh-Thu Le; Maurie Markman; Greg A Masters; Lisa Newman; Jennifer C Obel; Andrew D Seidman; Sonali M Smith; Nicholas Vogelzang; Nicholas J Petrelli
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(36):5327-47.
2010: Lorenzo Cohen; Zhen Chen; Banu Arun; Zhimin Shao; Mark Dryden; Linhhui Xu; Carisa Le-Petross; Basak Dogan; Brian J McKenna; Maurie Markman; Gildy Babiera
External qigong therapy for women with breast cancer prior to surgery.
Integrative cancer therapies 2010;9(4):348-53.
2010: Leslie M Randall; Bradley J Monk; James Moon; Ricardo Parker; Muthana S Al-Ghazi; Sharon P Wilczynski; John P Fruehauf; Maurie Markman; Robert A Burger
Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study.
Gynecologic oncology 2010;119(3):417-21.
2010: Maurie Markman
Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.
Cancer 2010;116(22):5116-8.
2010: Maurie Markman
Maintenance chemotherapy: an evolving and increasingly acceptable strategy in cancer management.
Current oncology reports 2010;12(6):349-51.
2010: Robert C Bast; Maurie Markman
Chemotherapy: A new standard combination for recurrent ovarian cancer?
Nature reviews. Clinical oncology 2010;7(10):559-60.
2010: Maurie Markman
Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors.
Gynecologic oncology 2010;119(1):170; author reply 170-1.
2010: Maurie Markman
Continued uncertainty regarding hyperthermic intraperitoneal chemotherapy in malignant peritoneal mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):e418; author reply e419.
2010: Abdalla Sholi; Martin A Martino; Martin M Martino; Megan Pirigyi; Norman G Rosenblum; Maurie Markman; Candace S Peterson; Angela R Bradbury; Gloria J Morris
Mucinous adenocarcinoma of the ovary.
Seminars in oncology 2010;37(4):314-20.
2010: Bryan T. J. Hennessy; Kirsten M Timms; Mark S Carey; Alexander Gutin; Larissa A Meyer; Darl D Flake; Victor Abkevich; Jennifer Potter; Dmitry Pruss; Pat Glenn; Yang Li; Jie Li; Ana M Gonzalez-Angulo; Karen Smith McCune; Maurie Markman; Russell R Broaddus; Jerry S Lanchbury; Karen H Lu; Gordon B Mills
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(22):3570-6.
2010: Maurie Markman
Serious ethical dilemma of single-agent pegylated liposomal Doxorubicin employed as a control arm in ovarian cancer chemotherapy trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(19):e319-20; author reply e321-2.
2010: Maurie Markman
Combination versus sequential cytotoxic chemotherapy in recurrent ovarian cancer: time for an evidence-based comparison.
Gynecologic oncology 2010;118(1):6-7.
2010: Maurie Markman
"Clinical benefit rate" in phase 2 gynecologic cancer trials: implying more than the data support?
Gynecologic oncology 2010;117(2):348-9.
2010: Maurie Markman
"Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer".
Gynecologic oncology 2010;117(2):390; author reply 391.
2010: Maurie Markman; Ryan Luce
Impact of the cost of cancer treatment: an internet-based survey.
Journal of oncology practice / American Society of Clinical Oncology 2010;6(2):69-73.
2010: Maurie Markman; James Moon; Sharon Wilczynski; Ana Maria Lopez; Kendrith M Rowland; David P Michelin; Victor J Lanzotti; Garnet L Anderson; David S Alberts
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.
Gynecologic oncology 2010;116(3):323-5.
2010: Rajul K Jain; J Jack Lee; David Hong; Maurie Markman; Jing Gong; Aung Naing; Jennifer Wheler; Razelle Kurzrock
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(4):1289-97.
2010: Maurie Markman
Therapeutic intent and misconception in early-phase clinical trials in the gynecologic malignancies.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2010;20(2):311-2.
2010: Maurie Markman
Proposal to rigorously evaluate the clinical benefits associated with a novel anti-neoplastic strategy outside the confines of a randomized trial.
Oncology 2010;79(5-6):321-3.
2010: Maurie Markman; Daniel Lieber
Early onset of platinum hypersensitivity in a dentist: a case report.
Case reports in oncology 2010;3(2):294-7.
2010: Maurie Markman
Diagnostic pathology: challenges and increasing complexity.
Oncology 2010;79(3-4):159-60.
2010: Simone Marnitz; Christhardt Köhler; Peter Oppelt; Alexander Schmittel; Giovanni Favero; Kati Hasenbein; Achim Schneider; Maurie Markman
Cisplatin application in pregnancy: first in vivo analysis of 7 patients.
Oncology 2010;79(1-2):72-7.
2010: Maurie Markman
A critical need to reconsider cancer trial eligibility requirements.
Oncology 2010;79(1-2):1-2.
2010: Maurie Markman
Recent studies that influence the chemotherapeutic paradigm in the management of advanced ovarian cancer.
F1000 medicine reports 2010;2():.
2010: Lisa N Abaid; Bram H Goldstein; John P Micha; Mark A Rettenmaier; John V Brown; Maurie Markman
Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma.
Oncology 2010;78(5-6):389-93.
2010: Maurie Markman
Expensive cytotoxic chemotherapy in the management of advanced cancers in the developing world.
Oncology 2010;78(1):3-4.
2010: Maurie Markman; Judith Petersen; Angela Belland; Kenda Burg
CA-125 monitoring in ovarian cancer: patient survey responses to the results of the MRC/EORTC CA-125 Surveillance Trial.
Oncology 2010;78(1):1-2.
2009: Nicholas J Petrelli; Eric P Winer; Julie R Brahmer; Sarita Dubey; Sonali Smith; Charles Thomas; Linda Vahdat; Jennifer Obel; Nicholas Vogelzang; Maurie Markman; John W Sweetenham; David G Pfister; Mark G Kris; Lynn Schuchter; Raymond Sawaya; Derek Raghavan; Patricia Anne Ganz; Barnett Kramer
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(35):6052-69.
2009: Maurie Markman
Optimal management of recurrent ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19 Suppl 2():S40-3.
2009: Maurie Markman
"Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma" Safra T, et al (Gynecol Oncol 2009; 114:215-218).
Gynecologic oncology 2009;115(3):514; author reply 514-5.
2009: Apostolia-Maria Tsimberidou; Christos Vaklavas; Sijin Wen; David Hong; Jennifer Wheler; Chaan Ng; Aung Naing; Susan Tse; Naifa L Busaidy; Maurie Markman; Steven I Sherman; Razelle Kurzrock
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.
The Journal of clinical endocrinology and metabolism 2009;94(11):4423-32.
2009: Maurie Markman
Comparative effectiveness research: a proposal for funding in ovarian cancer.
Gynecologic oncology 2009;115(2):182-3.
2009: Bryan T. J. Hennessy; Robert L Coleman; Maurie Markman
Ovarian cancer.
Lancet 2009;374(9698):1371-82.
2009: Maurie Markman
PET/CT scans in ovarian cancer: prognostic versus predictive utility?
Minerva medica 2009;100(5):415-20.
2009: Maurie Markman
Chemotherapy: Topotecan or treosulfan--that is the question.
Nature reviews. Clinical oncology 2009;6(10):559-60.
2009: Maurie Markman
Antiangiogenic drugs in ovarian cancer.
Expert opinion on pharmacotherapy 2009;10(14):2269-77.
2009: Maurie Markman
The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project.
Gynecologic oncology 2009;114(3):536; author reply 536-7.
2009: Harriet O Smith; James Moon; Sharon P Wilczynski; Amy D Tiersten; Edward V Hannigan; William R Robinson; Saul E Rivkin; Garnet L Anderson; Ping-Yu Liu; Maurie Markman
Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.
Gynecologic oncology 2009;114(2):206-9.
2009: Maurie Markman; P Y Liu; James Moon; Bradley J Monk; Larry Copeland; Sharon Wilczynski; David Alberts
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.
Gynecologic oncology 2009;114(2):195-8.
2009: Maurie Markman
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Gynecologic oncology 2009;114(1):136-7; authore reply 137.
2009: Maurie Markman
Presentation of chemotherapy options for cervix cancer on cancer-related Internet sites.
Journal of women's health (2002) 2009;18(6):827-9.
2009: Chunqiao Tian; Maurie Markman; Richard Zaino; Robert F Ozols; William P McGuire; Franco M Muggia; Peter G Rose; David Spriggs; Deborah K Armstrong
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.
Cancer 2009;115(7):1395-403.
2009: Maurie Markman
Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation.
Gynecologic oncology 2009;113(1):4-5.
2009: Maurie Markman
An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.
Cancer journal (Sudbury, Mass.) 2009;15(2):105-9.
2009: Kristin K Zorn; Chunqiao Tian; William P McGuire; William J Hoskins; Maurie Markman; Franco M Muggia; Peter G Rose; Robert F Ozols; David Spriggs; Deborah K Armstrong
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.
Cancer 2009;115(5):1028-35.
2009: Amy D Tiersten; P Y Liu; Harriet O Smith; Sharon P Wilczynski; William R Robinson; Maurie Markman; David S Alberts
Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
Gynecologic oncology 2009;112(3):444-9.
2009: Eric Winer; Julie Gralow; Lisa Diller; Beth Y Karlan; Patrick Loehrer; Lori J Pierce; George Demetri; Patricia Anne Ganz; Barnett Kramer; Mark G Kris; Maurie Markman; Robert Mayer; David G Pfister; Derek Raghavan; Scott Ramsey; Gregory Reaman; Howard Sandler; Raymond Sawaya; Lynn Schuchter; John Sweetenham; Linda Vahdat; Richard L Schilsky
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(5):812-26.
2009: Maurie Markman
Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin.
Therapeutics and clinical risk management 2009;5(1):161-8.
2009: John P Micha; Bram H Goldstein; Mark A Rettenmaier; John V Brown; Cameron R John; Maurie Markman
Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(2):239-41.
2009: Maurie Markman; Mark Brady; Alan Hutson; Jonathan S Berek
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(2):223-9.
2009: Maurie Markman
Update on the utility of prognostic biomarkers in ovarian cancer.
F1000 medicine reports 2009;1():.
2009: Amy D Tiersten; James Moon; Harriet O Smith; Sharon P Wilczynski; William R Robinson; Maurie Markman; David S Alberts
Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study.
Oncology 2009;77(6):395-9.
2009: James D Cox; Sergio Giralt; Mary L Veazie; Jaffer A Ajani; Janet M Bruner; Ka Wah Chan; Walter N Hittelman; Kelly K Hunt; Revathy B Iyer; Daniel D Karp; Deborah A Kuban; Scott M Lippman; Issam I Raad; Miguel A Rodriguez-Bigas; Leonard A Zwelling; Maurie Markman
Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience.
Oncology 2009;77(2):75-81.
2009: Maurie Markman
Hypersensitivity reactions: an increasingly recognized toxicity of platinum agents.
Oncology 2009;76(4):229-30.
2009: Maurie Markman
Therapeutic intent in the conduct of phase I antineoplastic drug trials.
Oncology 2009;76(3):149-50.
2009: Maurie Markman
The myth of measurable disease in ovarian cancer: revisited.
Cancer investigation 2009;27(1):11-2.
2008: Maurie Markman
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Cancer 2008;113(10):2832-3; author reply 2833-4.
2008: Maurie Markman
Predictive value of neoadjuvant chemotherapy for the clinical utility of subsequently performed major cancer surgery.
Current oncology reports 2008;10(6):447-8.
2008: Maurie Markman
Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
Trends in pharmacological sciences 2008;29(10):515-9.
2008: Maurie Markman
The remarkable "paclitaxel story": how many chapters remain to be written?
Gynecologic oncology 2008;111(1):7-8.
2008: Maurie Markman
Refocusing the debate: evidence-based clinical cancer research versus marketplace reality.
Journal of oncology practice / American Society of Clinical Oncology 2008;4(5):231.
2008: Maurie Markman
Risk of toxicity versus risk of death: a complex equation in the management of highly curable malignancies.
Current oncology reports 2008;10(5):359-60.
2008: Maurie Markman
Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: a strategy to improve the quality of gynecologic cancer clinical research.
Gynecologic oncology 2008;110(3):275-7.
2008: Maurie Markman
Assigning a cause for a particular outcome in oncology: a serious note of caution.
Cancer 2008;113(4):668-70.
2008: Maurie Markman
Diagnostic evaluations of unproven clinical utility in oncology: a real-life example of their harmful consequences.
Current oncology reports 2008;10(4):271-2.
2008: James Orr; Joseph Kelley; Don Dizon; Pedro Escobar; Evelyn Fleming; Mary L Gemignani; David Hetzel; William Hoskins; Dirk Kieback; Larry Kilgore; James LaPolla; Sharyn Lewin; Joseph Lucci; Maurie Markman; Bhavana Pothuri; C Bethan Powell; Trevor Tejada-Berges
Society of gynecologic oncologists position paper: breast cancer care.
Gynecologic oncology 2008;110(1):7-12.
2008: Maurie Markman
Second-line therapy for ovarian cancer.
Clinical advances in hematology & oncology : H&O 2008;6(6):421-2.
2008: Maurie Markman
Benefits of religious beliefs for cancer patients: a response to Dawkins and Hitchens.
Current oncology reports 2008;10(3):185-7.
2008: Maurie Markman
An ethical argument in support of interactions between developing world countries and pharmaceutical/biotechnology companies involved in oncology drug development.
Cancer 2008;112(9):1871-3.
2008: David S Alberts; Christian Marth; Ronald D Alvarez; Gary Johnson; Mariusz Bidzinski; David R Kardatzke; Williamson Z Bradford; Jeff Loutit; David H Kirn; Mary C Clouser; Maurie Markman
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Gynecologic oncology 2008;109(2):174-81.
2008: Amanda Fader; Vivian E von Gruenigen; Heidi Gibbons; Fadi Abushahin; David Starks; Maurie Markman; Jerome Belinson; Peter Rose
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Gynecologic oncology 2008;109(1):33-8.
2008: Maurie Markman
Evidence-based chemotherapy administration in advanced ovarian cancer: an impressive past, a disquieting present and an uncertain future.
Gynecologic oncology 2008;109(1):4-7.
2008: Maurie Markman
Combination versus sequential chemotherapy administration: is it time for a reevaluation of the issue?
Current oncology reports 2008;10(2):93-4.
2008: Maurie Markman
Maintenance chemotherapy in advanced ovarian cancer: the US experience.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18 Suppl 1():40-3.
2008: Maurie Markman
What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18 Suppl 1():36-9.
2008: Maurie Markman
Strategies to examine new compounds for intraperitoneal use in ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18 Suppl 1():33-5.
2008: Maurie Markman
"Conflict-of-interest" and participation in IRB deliberations: an alternative perspective.
Cancer investigation 2008;26(2):115-7.
2008: Maurie Markman
Re: "Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials".
Gynecologic oncology 2008;108(3):658; author reply 658-9.
2008: Maurie Markman
Critical thinking: an essential role in both the conduct and interpretation of gynecologic cancer clinical research.
Gynecologic oncology 2008;108(3):462-5.
2008: Maurie Markman
Taxanes in the management of gynecologic malignancies.
Expert review of anticancer therapy 2008;8(2):219-26.
2008: Maurie Markman
Objective data rather than opinion in the interpretation of the legitimate goals of phase 1 oncology trials.
Cancer investigation 2008;26(1):11-2.
2008: Maurie Markman
Prohibition against competing cancer clinical trials: a counter argument.
Cancer 2008;112(3):455-7.
2008: Julie R Gralow; Robert F Ozols; Dean F Bajorin; Bruce D Cheson; Howard M Sandler; Eric P Winer; James Bonner; George D Demetri; Walter Curran; Patricia Anne Ganz; Barnett S Kramer; Mark G Kris; Maurie Markman; Robert J Mayer; Derek Raghavan; Scott Ramsey; Gregory H Reaman; Raymond Sawaya; Lynn Schuchter; John W Sweetenham; Linda Vahdat; Nancy E Davidson; Richard L Schilsky; Allen S Lichter
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):313-25.
2008: Maurie Markman
The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Oncology 2008;74(1-2):1-6.
2008: Maurie Markman
Pharmaceutical management of ovarian cancer : current status.
Drugs 2008;68(6):771-89.
2008: Maurie Markman
The increasingly complex world of cancer patient advocacy organizations.
Current oncology reports 2008;10(1):1-2.
2008: David S Alberts; Ping-Yu Liu; Sharon P Wilczynski; Mary C Clouser; Ana Maria Lopez; David P Michelin; Victor J Lanzotti; Maurie Markman
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
Gynecologic oncology 2008;108(1):90-4.
2008: Maurie Markman; Judy Petersen; Robert Montgomery
An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials.
Journal of cancer research and clinical oncology 2008;134(1):115-8.
2007: Maurie Markman
The role of independent review to insure ethical quality-improvement activities in oncology: a commentary on the national debate regarding the distinction between quality-improvement initiatives and clinical research.
Cancer 2007;110(12):2597-600.
2007: Maurie Markman
"Of models and men (or women)"--a brief story of a mathematical model and its influence on the management of ovarian cancer.
Cancer investigation 2007;25(8):666-7.
2007: Jonathan R Markman; Maurie Markman
Running an ethical trial 60 years after the Nuremberg Code.
The lancet oncology 2007;8(12):1139-46.
2007: Ehab Atallah; Jorge Cortes; Susan O'Brien; Sherry Pierce; Mary Beth Rios; Elihu Estey; Maurie Markman; Michael Keating; Emil J Freireich; Andrew Lamb
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
Blood 2007;110(10):3547-51.
2007: Maurie Markman
Standard of care versus standards of care in oncology: a not so subtle distinction.
Journal of oncology practice / American Society of Clinical Oncology 2007;3(6):291.
2007: Maurie Markman
HPV vaccination and the prevention of cervical cancer: the long road ahead.
Journal of women's health (2002) 2007;16(9):1366-7.
2007: Maurie Markman
Diagnostic dilemmas in cancer medicine: focusing on the treatable.
Current oncology reports 2007;9(6):429-30.
2007: Maurie Markman
The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancer.
Nature clinical practice. Oncology 2007;4(11):628-9.
2007: Maurie Markman
The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management.
Gynecologic oncology 2007;107(2):163-5.
2007: Maurie Markman
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution.
Cancer 2007;110(8):1644-7.
2007: Maurie Markman
Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4168-70.
2007: Maurie Markman
Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: efficacy, toxicity, and future directions.
Reviews on recent clinical trials 2007;2(3):169-73.
2007: Maurie Markman
Recognizing the toxicity of "nontoxic" drugs employed in the management of malignant disease.
Current oncology reports 2007;9(5):329-30.
2007: William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3621-7.
2007: Ping-Yu Liu; David S Alberts; Bradley J Monk; Mark Brady; James Moon; Maurie Markman
An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3615-20.
2007: Maurie Markman
Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3554; author reply 3557-8.
2007: Maurie Markman
Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
Gynecologic oncology 2007;106(2):279-81.
2007: Maurie Markman
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Gynecologic oncology 2007;106(2):433.
2007: Maurie Markman
Mentoring in the ethics of clinical research: an ongoing need.
Current oncology reports 2007;9(4):235-6.
2007: Maurie Markman
Development of an ovarian cancer symptom index: possibilities for earlier detection.
Cancer 2007;110(1):226; author reply 227.
2007: Maurie Markman
Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer.
Gynecologic oncology 2007;106(1):273-4; author reply 274-5.
2007: David S Alberts; Ping-Yu Liu; Sharon P Wilczynski; A Jang; J Moon; J H Ward; J T Beck; Mary C Clouser; Maurie Markman
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(4):784-8.
2007: Maurie Markman
Human papillomavirus vaccines to prevent cervical cancer.
Lancet 2007;369(9576):1837-9.
2007: Ralph S Freedman; Maurie Markman
Food and drug administration expanded access to treatment: implications for oncology patients.
Cancer 2007;109(11):2157-60.
2007: Maurie Markman
A relevant historical perspective on the current toxicity of IP chemotherapy: implications for the future.
Gynecologic oncology 2007;105(3):561-2.
2007: Maurie Markman
The dangers of "cross-trial" and "cross-retrospective experience" comparisons: examples employing data in the peer-reviewed ovarian cancer literature.
Cancer 2007;109(10):1929-32.
2007: Maurie Markman
Use of progression-free survival as a valid endpoint in phase II cancer clinical trials.
Current oncology reports 2007;9(3):159-60.
2007: Ronald M Bukowski; Robert F Ozols; Maurie Markman
The management of recurrent ovarian cancer.
Seminars in oncology 2007;34(2 Suppl 2):S1-15.
2007: Maurie Markman
Effect of obesity on survival in epithelial ovarian cancer.
Cancer 2007;109(7):1446; author reply 1447.
2007: Maurie Markman
Re: "Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study".
Gynecologic oncology 2007;105(1):279-80; author reply 280-1.
2007: Maurie Markman
Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncology.
Cancer 2007;109(6):1003-6.
2007: Maurie Markman
Care of the incarcerated cancer patient.
Current oncology reports 2007;9(2):81-2.
2007: Maurie Markman
Re: "En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report".
Gynecologic oncology 2007;104(3):781; author reply 781-2.
2007: Howard D Homesley; Virginia Filiaci; Maurie Markman; Pincas Bitterman; Lynne Eaton; Larry C Kilgore; Bradley J Monk; Frederick R Ueland
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):526-31.
2007: Maurie Markman
New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
The oncologist 2007;12(2):186-90.
2007: Maurie Markman
The objectivity of reports describing the use of novel diagnostic tests in the management of ovarian cancer: a critique.
Gynecologic oncology 2007;104(2):271-2.
2007: Maurie Markman
Comorbidity as a focus of clinical cancer trials: an important unmet need.
Oncology 2007;73(5-6):279-80.
2007: Maurie Markman
Development of an effective breast and cervix cancer screening strategy in Mumbai: an impressive effort.
Oncology 2007;73(3-4):143-4.
2007: Maurie Markman
Reducing the worldwide burden of cancer.
Oncology 2007;73(1-2):1.
2007: Maurie Markman
The rapidly changing oncology landscape: a time for transition in oncology.
Oncology 2007;72(5-6):417-8.
2007: Maurie Markman
Are we entering the era of maintenance therapy of advanced malignant disease?
Oncology 2007;72(5-6):265-6.
2007: Maurie Markman
A need to document a role for palliative chemotherapy in the management of progressive malignant disease.
Oncology 2007;72(3-4):162-3.
2007: Maurie Markman
Use of systemic antineoplastic drug therapy after regulatory agency approval.
Oncology 2007;72(3-4):145-6.
2007: Maurie Markman
Increasing entry of the elderly into cancer clinical trials: difficult, but unquestionably necessary.
Oncology 2007;72(1-2):2-3.
2007: Maurie Markman
Justification for separate consideration of two broad categories of cancer patient use of complementary medicine.
Journal of the Society for Integrative Oncology 2007;5(2):50-2.
2007: Maurie Markman
Intraperitoneal chemotherapy in the management of ovarian cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2007;169():165-76.
2007: Maurie Markman
Cancer screening: understanding barriers to optimal use of evidence-based strategies.
Journal of women's health (2002) 2007;16(1):9-10.
2007: Maurie Markman; Larie Smoyer; J Timothy Marron; Robert Montgomery
Cancer versus heart failure patient self-declared potential interest in clinical trials.
Current oncology reports 2007;9(1):1-5.
2007: Robert F Ozols; Roy S Herbst; Yolonda L Colson; Julie R Gralow; James Bonner; Walter Curran; Burton L Eisenberg; Patricia Anne Ganz; Barnett S Kramer; Mark G Kris; Maurie Markman; Robert J Mayer; Derek Raghavan; Gregory H Reaman; Raymond Sawaya; Richard L Schilsky; Lynn Schuchter; John W Sweetenham; Linda Vahdat; Rodger J Winn
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):146-62.
2007: Peter G Rose; Benjamin E Greer; Ira R Horowitz; Maurie Markman; Nancy Fusco
Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Gynecologic oncology 2007;104(1):114-9.
2006: Maurie Markman
Clinical efficacy supporting the role of intraperitoneal drug delivery in the primary chemotherapeutic management of small-volume residual advanced ovarian cancer.
Seminars in oncology 2006;33(6 Suppl 12):S3-7.
2006: David S Alberts; Maurie Markman; Franco Muggia; Robert F Ozols; E Eldermire; Michael A Bookman; T Chen; J Curtin; L M Hess; Leonard Liebes; R C Young; E Trimble
Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.
Gynecologic oncology 2006;103(3):783-92.
2006: Maurie Markman
Hormonal therapy for epithelial ovarian cancer.
Women's health (London, England) 2006;2(6):847-51.
2006: Maurie Markman
The role of intraperitoneal chemotherapy in ovarian cancer.
Clinical advances in hematology & oncology : H&O 2006;4(11):809-10.
2006: Maurie Markman
Evaluation of the clinical utility of diagnostic versus therapeutic interventions in oncology: related but quite different processes.
Current oncology reports 2006;8(6):407-8.
2006: Marisa Navo; Anuradha Kunthur; Martina L Badell; Larry W Coffer; Maurie Markman; Jubilee Brown; Judith A Smith
Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
Gynecologic oncology 2006;103(2):608-13.
2006: Deborah K Armstrong; Gini F Fleming; Maurie Markman; Howard H Bailey
A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
Gynecologic oncology 2006;103(2):391-6.
2006: Maurie Markman; Massimo Federico; P Y Liu; Edward Hannigan; David S Alberts
Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Gynecologic oncology 2006;103(1):195-8.
2006: Elisa Tso; Paul Elson; Fred Vanlente; Maurie Markman
The "real-life" variability of CA-125 in ovarian cancer patients.
Gynecologic oncology 2006;103(1):141-4.
2006: Maurie Markman
The "new" era of oral antineoplastic drug therapy: revisiting "old" concerns.
Current oncology reports 2006;8(5):317-8.
2006: Maurie Markman
Descriptions in the peer-reviewed literature of the results of phase 2 chemotherapy trials involving gynecologic malignancies: a call for greater objectivity.
Gynecologic oncology 2006;102(3):419-20.
2006: Maurie Markman; Judith Petersen; Robert Montgomery
Influence of tumor type, disease status, and patient age on self-reported interest regarding participation in cancer clinical trials.
Cancer 2006;107(4):849-53.
2006: Maurie Markman
Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary.
Expert opinion on pharmacotherapy 2006;7(11):1469-74.
2006: Maurie Markman
Chemotherapy-induced peripheral neuropathy: underreported and underappreciated.
Current pain and headache reports 2006;10(4):275-8.
2006: Thomas J Herzog; Robert L Coleman; Maurie Markman; David Cella; J Tate Thigpen
The role of maintenance therapy and novel taxanes in ovarian cancer.
Gynecologic oncology 2006;102(2):218-25.
2006: Peter G Rose; Maurie Markman; Jeffrey G Bell; Nancy Fusco
Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
Gynecologic oncology 2006;102(2):236-9.
2006: Maurie Markman
"Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
Archives of internal medicine 2006;166(14):1446-8.
2006: Maurie Markman
Normal CA-125 and the risk of progression in ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(20):3310; author reply 3310-1.
2006: Maurie Markman
The diagnostic "gold standard" in oncology: increasing importance and increasing concerns.
Current oncology reports 2006;8(4):237-8.
2006: Maurie Markman; Margaret Markman; Judith Petersen; Angela Belland
Clinical features of American versus non-American gynecologic cancer patients requesting information from a proprietary web-based decision-support program.
Journal of cancer research and clinical oncology 2006;132(7):439-43.
2006: Maurie Markman
Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.
Gynecologic oncology 2006;101(3):550-1; author reply 551-2.
2006: Maurie Markman; John A Blessing; Stephen C Rubin; Joseph Connor; Parviz Hanjani; Steven Waggoner
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
Gynecologic oncology 2006;101(3):436-40.
2006: Maurie Markman
Quality assurance in oncology.
Current oncology reports 2006;8(3):155-56.
2006: John P Micha; Bram H Goldstein; Mark A Rettenmaier; John V Brown; Cameron R John; Maurie Markman
Surgery alone or surgery with a combination radiation or chemoradiation for management of patients with bulky-stage IB2 cervical carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(3):1147-51.
2006: Maurie Markman
Palliative chemotherapy "near the end-of-life" in ovarian cancer: not necessarily "aggressive cure-oriented therapy".
Gynecologic oncology 2006;101(2):198-9.
2006: Maurie Markman
Unresolved issues in the chemotherapeutic management of gynecologic malignancies.
Seminars in oncology 2006;33(2 Suppl 6):S33-8.
2006: Maurie Markman
Management of ovarian cancer. An impressive history of improvement in survival and quality of life.
Oncology (Williston Park, N.Y.) 2006;20(4):347-54; discussion 354, 357-8, 364 passim.
2006: Maurie Markman; Margaret R Markman; Angela Belland; Judith Petersen
Profile of ovarian cancer patients seeking information from a web-based decision support program.
Journal of women's health (2002) 2006;15(3):312-8.
2006: Maurie Markman
Providing research participants with findings from completed cancer-related clinical trials: not quite as simple as it sounds.
Cancer 2006;106(7):1421-4.
2006: Maurie Markman; P Y Liu; Mace L Rothenberg; Bradley J Monk; Mark Brady; David S Alberts
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(9):1454-8.
2006: Maurie Markman
Cancer survivorship: the concept and the increasingly recognized reality.
Current oncology reports 2006;8(2):79-80.
2006: Maurie Markman; Joan L Walker
Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):988-94.
2006: Peter F Thall; Elihu H Estey; Maurie Markman
Some ethical issues in phase II trials in acute leukemia.
Clinical advances in hematology & oncology : H&O 2006;4(2):95.
2006: Maurie Markman
Another example of the highly variable clinical course of recurrent/resistant/persistent ovarian cancer.
Cancer investigation 2006;24(1):109.
2006: Maurie Markman
Re: "Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival".
Gynecologic oncology 2006;100(2):443; author reply 444.
2006: Maurie Markman
Viewing ovarian cancer as a "chronic disease": what exactly does this mean?
Gynecologic oncology 2006;100(2):229-30.
2006: Maurie Markman
Optimizing management of recurrent epithelial ovarian cancer: a critical need for evidence-based data.
Oncology 2006;71(5-6):309-11.
2006: Maurie Markman
Efforts to define a role for recombinant erythropoietin in cancer management.
Oncology 2006;71(3-4):149-50.
2006: John P Micha; Bram H Goldstein; Cheri Graham; Mark A Rettenmaier; John V Brown; Jim C Hu; Maurie Markman
Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma.
Oncology 2006;71(1-2):49-53.
2006: Maurie Markman
Presentations of phase 2 clinical trial abstracts at a national oncology meeting: potential implications for subsequent publication in the peer-reviewed literature.
Oncology 2006;71(1-2):146-7.
2006: Maurie Markman
Turning cervix cancer into a "rare disease": is society prepared to do what is required to make this a reality?
Current oncology reports 2006;8(1):1-2.
2006: Harriet O Smith; Caroline S Jiang; Geoffrey R Weiss; Alton V Hallum; Ping-Yu Liu; W R Robinson; P C Cheng; Sidney A Scudder; Maurie Markman; David S Alberts
Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(1):298-305.
2006: Roy S Herbst; Dean F Bajorin; Harry Bleiberg; Diane Blum; Desirée Hao; Bruce E Johnson; Robert F Ozols; George D Demetri; Patricia Anne Ganz; Mark G Kris; Bernard Levin; Maurie Markman; Derek Raghavan; Gregory H Reaman; Raymond Sawaya; Lynn Schuchter; John W Sweetenham; Linda Vahdat; Everett E Vokes; Rodger J Winn; Robert J Mayer
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):190-205.
2006: Maurie Markman
Assuring the ethical conduct of clinical cancer trials in the developing world.
Cancer 2006;106(1):1-3.
2006: David S Alberts; Edward V Hannigan; Ping-Yu Liu; Caroline Jiang; Sharon P Wilczynski; Larry Copeland; Maurie Markman
Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study.
Gynecologic oncology 2006;100(1):133-8.
2005: J Michael Straughn; T Michael Numnum; Larry C Kilgore; Edward E Partridge; Jerri Linn Phillips; Maurie Markman; Gillian M Thomas; Thomas W Burke
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base.
Gynecologic oncology 2005;99(3):530-5.
2005: Maurie Markman
Fever of unknown origin and cancer: a clinically meaningful association.
The lancet oncology 2005;6(11):821-2.
2005: Maurie Markman
A "snapshot" of an ovarian cancer clinical practice: evidence for viewing the malignancy as a "chronic disease".
Current oncology reports 2005;7(6):393-4.
2005: Maurie Markman
Use of positron emission tomography scans in ovarian cancer: a diagnostic technique in search of an indication.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7385-7.
2005: Maurie Markman
Chemosensitivity and chemoresistance testing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(29):7363-4.
2005: Maurie Markman
Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity.
The oncologist 2005;10(9):695-7.
2005: Timothy M Markman; Maurie Markman
The patient and Web-based cancer information: a role for provider input into this rapidly evolving relationship.
Current oncology reports 2005;7(5):313-4.
2005: Denise Uyar; Heidi E Frasure; Maurie Markman; Vivian E von Gruenigen
Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer.
Gynecologic oncology 2005;98(3):403-8.
2005: Chad M Michener; Gertrude Peterson; Barbara Kulp; Kenneth D Webster; Maurie Markman
Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
Journal of cancer research and clinical oncology 2005;131(9):581-4.
2005: Maurie Markman
Unique issues in the development of "targeted" antineoplastic pharmaceutical agents.
Current oncology reports 2005;7(4):235-6.
2005: Robert J Kim; Gertrude Peterson; Barbara Kulp; Kristine Zanotti; Maurie Markman
Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
Gynecologic oncology 2005;97(2):374-8.
2005: Maurie Markman
Chemotherapy-induced peripheral neuropathy: an increasing concern for oncologists.
Current oncology reports 2005;7(3):159-60.
2005: Keiichi Fujiwara; Maurie Markman; Mark Morgan; Robert L Coleman
Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
Gynecologic oncology 2005;97(1):10-5.
2005: Maurie Markman
Hormonal therapy of endometrial cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(5):673-5.
2005: Sidney A Scudder; Ping-Yu Liu; Sharon P Wilczynski; Harriet O Smith; Caroline Jiang; Alton V Hallum; Gregory B Smith; Edward V Hannigan; Maurie Markman; David S Alberts
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Gynecologic oncology 2005;96(3):610-5.
2005: Maurie Markman
Care of pediatric cancers in the developing world: should this be a societal priority?
Current oncology reports 2005;7(2):81-2.
2005: Maurie Markman
Reflections on ethical concerns arising from the incorporation of results of randomized trials of antineoplastic therapy into routine clinical practice.
Cancer investigation 2005;23(8):735-40.
2005: Maurie Markman; Judith Petersen; Robert Montgomery
An examination of characteristics of lung and colon cancer patients participating in a web-based decision support program. Internet-based decision support programs.
Oncology 2005;69(4):311-6.
2005: Maurie Markman
Supportive care.
Cancer chemotherapy and biological response modifiers 2005;22():677-86.
2005: Maurie Markman; Kenneth Webster; Barbara Kulp; Gertrude Peterson
Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (>1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications.
Cancer investigation 2005;23(1):33-5.
2005: Maurie Markman
'Flat-fixed dosing' of chemotherapy: a concept whose time has come?
Current oncology reports 2005;7(1):1-2.
2005: John P Micha; Bram H Goldstein; Julie A Mattison; Kathy Bader; Cheri Graham; Mark A Rettenmaier; John V Brown; Maurie Markman
Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Gynecologic oncology 2005;96(1):132-5.
2005: J Tate Thigpen; Carol Aghajanian; David S Alberts; Susana Campos; Alan N Gordon; Maurie Markman; D Scott McMeekin; Bradley J Monk; Peter G Rose
Role of pegylated liposomal doxorubicin in ovarian cancer.
Gynecologic oncology 2005;96(1):10-8.
2005: Maurie Markman; Jerome Belinson
A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.
Journal of cancer research and clinical oncology 2005;131(1):26-30.
2004: Maurie Markman; Alan N Gordon; William P McGuire; Franco M Muggia
Liposomal anthracycline treatment for ovarian cancer.
Seminars in oncology 2004;31(6 Suppl 13):91-105.
2004: Mace L Rothenberg; Ping-Yu Liu; Sharon P Wilczynski; William A Nahhas; Gaye L Winakur; Caroline S Jiang; Carol M Moinpour; Ben Lyons; Geoffrey R Weiss; James H Essell; Harriet O Smith; Maurie Markman; David S Alberts
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.
Gynecologic oncology 2004;95(3):506-12.
2004: Maurie Markman; Jon Markman; Kenneth Webster; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers.
Journal of cancer research and clinical oncology 2004;130(12):741-4.
2004: Maurie Markman
Point: Intraperitoneal chemotherapy in the management of ovarian cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2(6):549-54.
2004: Maurie Markman
Recent reminders of why the gold standard for clinical research in oncology is the well-designed and conducted randomized phase III trial.
Current oncology reports 2004;6(6):421-2.
2004: Maurie Markman
Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
Journal of cancer research and clinical oncology 2004;130(11):645-8.
2004: Robert S Lavey; P Y Liu; Benjamin E Greer; William R Robinson; Pui C Chang; Raymond B. Wynn; Marcel E Conrad; Caroline Jiang; Maurie Markman; David S Alberts
Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study.
Gynecologic oncology 2004;95(1):145-51.
2004: Maurie Markman; Kenneth Webster; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
Gynecologic oncology 2004;95(1):109-13.
2004: Maurie Markman
What is the clinically relevant endpoint for cancer prevention trials?
Current oncology reports 2004;6(5):329-30.
2004: Maurie Markman; Barbara Kulp; Gertrude Peterson
Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
Gynecologic oncology 2004;94(2):578-80.
2004: Maurie Markman; Kenneth Webster; Kristine Zanotti; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
Gynecologic oncology 2004;94(2):404-8.
2004: Maurie Markman; Jonathan Markman; Kenneth Webster; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3120-5.
2004: Maurie Markman
Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103.
Journal of experimental therapeutics & oncology 2004;4(2):131-6.
2004: Denise Uyar; Barbara Kulp; Gertrude Peterson; Kristine Zanotti; Maurie Markman; Jerome Belinson
Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
Gynecologic oncology 2004;94(1):147-51.
2004: Maurie Markman
Translating the results of phase III randomized cancer trials into the language of physician obligation to patients.
Current oncology reports 2004;6(4):243-4.
2004: Maurie Markman
Experience with platinum-based and high-dose chemotherapy in patients with gestational trophoblastic disease: possible implications for future management.
Journal of cancer research and clinical oncology 2004;130(7):383-7.
2004: Maurie Markman; Kenneth Webster; Kristine Zanotti; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer.
Gynecologic oncology 2004;93(3):715-7.
2004: Maurie Markman; Kenneth Webster; Kristine Zanotti; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
Gynecologic oncology 2004;93(3):699-701.
2004: Maurie Markman
What must research subjects be told regarding the results of completed randomized trials?
IRB 2004;26(3):8-10.
2004: Maurie Markman; Kenneth Webster; Kristine Zanotti; Jacqueline Rohl; Jerome Belinson
Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer.
Gynecologic oncology 2004;93(2):390-3.
2004: Maurie Markman
Intraperitoneal hyperthermic chemotherapy as treatment of peritoneal carcinomatosis of colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1527; author reply 1529.
2004: David S Alberts; Caroline Jiang; Ping-Yu Liu; Sharon P Wilczynski; Maurie Markman; Mace L Rothenberg
Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(2):224-8.
2004: Maurie Markman
Duration of chemotherapy in low-versus high-volume metastatic cancer: should there be a difference?
Current oncology reports 2004;6(2):75-6.
2004: Jonathan Markman; Kristine Zanotti; Kenneth Webster; Jerome Belinson; Gertrude Peterson; Barbara Kulp; Maurie Markman
Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Gynecologic oncology 2004;92(2):592-5.
2004: Joseph P DeMarco; Maurie Markman
The research misconception.
The International journal of applied philosophy 2004;18(2):241-52.
2004: Maurie Markman
Can we do a better job preventing clinically-relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy?
Cancer investigation 2004;22(3):471-3.
2004: Maurie Markman; Jerome Belinson; Kenneth Webster; Kristine Zanotti; Bei Morrison; Barbara Jacobs; Ernest C Borden; Daniel J Lindner
Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum.
Oncology 2004;66(5):343-6.
2004: Maurie Markman
Ethical conflict in providing informed consent for clinical trials: a problematic example from the gynecologic cancer research community.
The oncologist 2004;9(1):3-7.
2004: Pedro F Escobar; Maurie Markman; Peter Rose; Kristine Zanotti; Kenneth Webster; Jerome Belinson
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
Gynecologic oncology 2004;92(1):192-6.
2004: Maurie Markman; Jeffrey Fowler
Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel.
Gynecologic oncology 2004;92(1):180-2.
2004: Maurie Markman
Genetic discrimination arising from cancer risk assessments: a societal dilemma.
Cleveland Clinic journal of medicine 2004;71(1):12, 15-8.
2004: Maurie Markman
Is it time for oncologists to modify their laissez-faire attitude toward alternative/complementary 'drug therapy'?
Current oncology reports 2004;6(1):1-2.
2004: Maurie Markman; Fred Hsieh; Kristine Zanotti; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Ann Spicel; Jerome Belinson
Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.
Journal of cancer research and clinical oncology 2004;130(1):25-8.
2003: Maurie Markman; Kristine Zanotti; Gertrude Peterson; Barbara Kulp; Kenneth Webster; Jerome Belinson
Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4611-4.
2003: Maurie Markman
The needs of science vs the needs of patients: ethical concerns in cancer clinical trials.
Cleveland Clinic journal of medicine 2003;70(12):1008-9, 1013-4, 1016.
2003: Maurie Markman; Kristine Zanotti; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
Gynecologic oncology 2003;91(3):573-6.
2003: Maurie Markman
Prevention of paclitaxel-associated arthralgias and myalgias.
The journal of supportive oncology 2003;1(4):233-4.
2003: Joseph P DeMarco; Maurie Markman
Clinical equipoise: more uncertainty.
The Hastings Center report 2003;33(6):4; author reply 4-5.
2003: Maurie Markman
Consolidation therapy revisited: intravenous chemotherapy.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():204-7.
2003: Benjamin M Schwartz; Deepak Khuntia; Alexander W Kennedy; Maurie Markman
Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy.
Gynecologic oncology 2003;91(2):421-2.
2003: Maurie Markman
Toxicities of the platinum antineoplastic agents.
Expert opinion on drug safety 2003;2(6):597-607.
2003: Maurie Markman
Consolidation/maintenance chemotherapy for ovarian cancer.
Current oncology reports 2003;5(6):454-8.
2003: Maurie Markman
Surgical staging of cancer: impact on prognosis and potential for bias in clinical trials.
Current oncology reports 2003;5(6):437-8.
2003: Pedro F Escobar; Maurie Markman; Kristine Zanotti; Kenneth Webster; Jerome Belinson
Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer.
Journal of cancer research and clinical oncology 2003;129(11):651-4.
2003: Denise Uyar; Nagio Takigawa; Tarek Mekhail; Dale R Grabowski; Maurie Markman; Francis Lee; Renzo Canetta; Ron Peck; Ronald Bukowski; Ram Ganapathi
Apoptotic pathways of epothilone BMS 310705.
Gynecologic oncology 2003;91(1):173-8.
2003: Maurie Markman; Paul Elson; Barbara Kulp; Gertrude Peterson; Kristine Zanotti; Kenneth Webster; Jerome Belinson
Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia.
Gynecologic oncology 2003;91(1):118-22.
2003: Maurie Markman; Kenneth Webster; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
Gynecologic oncology 2003;90(3):593-6.
2003: Maurie Markman
Informing patients with cancer of "new findings" that may influence their willingness to participate in research studies.
Cancer 2003;98(5):885-7.
2003: Maurie Markman
Randomized trials in oncology: a fertile ground for controversy.
Current oncology reports 2003;5(5):347-8.
2003: Maurie Markman
The myth of measurable disease in ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(16):3013-5.
2003: Maurie Markman
Optimizing primary chemotherapy in ovarian cancer.
Hematology/oncology clinics of North America 2003;17(4):957-68, viii.
2003: Maurie Markman; Joseph DeMarco
Potential conflict between fundamental ethical principles and requirements of the oncology drug approval process: ethical conflict in drug approval.
Cancer 2003;98(2):215-8.
2003: Maurie Markman
Are we winning or losing the war on cancer?
Cleveland Clinic journal of medicine 2003;70(7):632-3.
2003: Maurie Markman
Outcomes of two antiemetic therapies are the same.
Oncology nursing forum 2003;30(4):551-5; author reply 551-5.
2003: Maurie Markman; P Y Liu; Sharon Wilczynski; Bradley Monk; Larry J Copeland; Ronald D Alvarez; Caroline Jiang; David Alberts
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2460-5.
2003: Maurie Markman
Limitations to the use of the CA-125 antigen level in ovarian cancer.
Current oncology reports 2003;5(4):263-4.
2003: Maurie Markman; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Maurie Markman
Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.
Gynecologic oncology 2003;89(3):514-6.
2003: Allan Covens; Virginia L Brunetto; Maurie Markman; James W Orr; Samuel S Lentz; Jo Benda
Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study.
Gynecologic oncology 2003;89(3):470-4.
2003: Maurie Markman
Role of intraperitoneal chemotherapy in the front-line setting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10 Suppl):145s-148s.
2003: Stephen A Cannistra; Robert C Bast; Jonathan S Berek; Michael A Bookman; Christopher P Crum; Paul D DePriest; Judy E Garber; Wui-Jin Koh; Maurie Markman; William P McGuire; Peter G Rose; Eric K Rowinsky; Gordon J S Rustin; Steven J Skates; Paul A Vasey; Laura King
Progress in the management of gynecologic cancer: consensus summary statement.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10 Suppl):129s-132s.
2003: Maurie Markman
Does palliative chemotherapy palliate?
The journal of supportive oncology 2003;1(1):65-7.
2003: Maurie Markman; Kristine Zanotti; Kenneth Webster; Jerome Belinson; Peter Rose
Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.
Oncology (Williston Park, N.Y.) 2003;17(5 Suppl 5):34-5.
2003: Maurie Markman
Intraperitoneal antineoplastic drug delivery: rationale and results.
The lancet oncology 2003;4(5):277-83.
2003: Mace L Rothenberg; Ping-Yu Liu; Patricia S Braly; Sharon P Wilczynski; Edward V Hannigan; Scott Wadler; Gavin Stuart; Caroline Jiang; Maurie Markman; David S Alberts
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(7):1313-9.
2003: Maurie Markman
Rationale for maintenance or consolidation therapy in ovarian cancer.
Clinical advances in hematology & oncology : H&O 2003;1(3):176-8.
2003: Maurie Markman
Management of toxicities associated with the administration of taxanes.
Expert opinion on drug safety 2003;2(2):141-6.
2003: Maurie Markman; Tracy Glass; Harriet O Smith; Kenneth D Hatch; Geoffrey R Weiss; Sarah A Taylor; J Wendall Goodwin; David S Alberts
Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
Gynecologic oncology 2003;88(3):282-8.
2003: Maurie Markman
Managing taxane toxicities.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2003;11(3):144-7.
2003: Yan Xu; Yi-jin Xiao; Kui Zhu; Linnea M Baudhuin; Jun Lu; Guiying Hong; Kwan-Sik Kim; Kelly L Cristina; Li Song; Freager S Williams; Paul Elson; Maurie Markman; Jerome Belinson
Unfolding the pathophysiological role of bioactive lysophospholipids.
Current drug targets. Immune, endocrine and metabolic disorders 2003;3(1):23-32.
2003: Maurie Markman
Supportive care.
Cancer chemotherapy and biological response modifiers 2003;21():709-16.
2003: Maurie Markman
Is there a role for aggressive surgical cytoreduction in patients with known metastatic cancer?
Current oncology reports 2003;5(1):1-2.
2002: Robert F Ozols; Maurie Markman; J Tate Thigpen
ICON3 and chemotherapy for ovarian cancer.
Lancet 2002;360(9350):2086-7; author reply 2088.
2002: Maurie Markman
Challenging ovarian cancer: how can we improve quantity and quality of life?
MedGenMed : Medscape general medicine 2002;4(4):10.
2002: Maurie Markman
Advertising genetic testing.
The Hastings Center report 2002;32(6):5.
2002: David S Alberts; Maurie Markman; Deborah K Armstrong; Mace L Rothenberg; Franco Muggia; Stephen B Howell
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):3944-6.
2002: Maurie Markman
Safety issues in using complementary and alternative medicine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18 Suppl):39S-41S.
2002: Maurie Markman
The prophylactic administration of recombinant erythropoietin in the management of ovarian cancer: time for a definitive phase 3 randomized trial.
Gynecologic oncology 2002;86(3):237-8.
2002: Maurie Markman
Does palliative chemotherapy palliate?
Current oncology reports 2002;4(5):361.
2002: Maurie Markman
Progress in preventing chemotherapy-induced nausea and vomiting.
Cleveland Clinic journal of medicine 2002;69(8):609-10, 612, 615-7.
2002: Maurie Markman; Barbara Kulp; Gertrude Peterson; Alexander Kennedy; Jerome Belinson
Second-line therapy of ovarian cancer with Paclitaxel administered by both the intravenous and intraperitoneal routes: rationale and case reports.
Gynecologic oncology 2002;86(1):95-8.
2002: Margaret R Markman; Gertrude Peterson; Barbara Kulp; Maurie Markman
Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
Gynecologic oncology 2002;85(3):435-7.
2002: Tarek Mekhail; Maurie Markman
Paclitaxel in cancer therapy.
Expert opinion on pharmacotherapy 2002;3(6):755-66.
2002: Maurie Markman
Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'?
Cleveland Clinic journal of medicine 2002;69(5):368-9, 375-6.
2002: Maurie Markman; James Hall; Daniel Spitz; Sheldon Weiner; Linda Carson; Linda Van Le; Mark Baker
Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2365-9.
2002: Maurie Markman
The use of PET scanning in ovarian cancer.
Gynecologic oncology 2002;85(2):391; author reply 391-2.
2002: Jeffrey D Bloss; John A Blessing; Brent C Behrens; Robert S Mannel; Janet S Rader; Anil K Sood; Maurie Markman; Jo Ann Benda
Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(7):1832-7.
2002: Maurie Markman
Role of chemotherapy in the management of ovarian cancer.
Expert review of anticancer therapy 2002;2(1):90-6.
2002: Maurie Markman
Second-line treatment of ovarian cancer with single-agent gemcitabine.
Seminars in oncology 2002;29(1 Suppl 1):9-10.
2002: Richard R Barakat; Paul Sabbatini; Dharmendra Bhaskaran; Margarita Revzin; Alex Smith; Venkatraman E Seshan; Carol Aghajanian; Martee Hensley; Steven L Soignet; Carol L Brown; Robert A Soslow; Maurie Markman; William J Hoskins; David Spriggs
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):694-8.
2002: Maurie Markman
Hypersensitivity reactions to carboplatin.
Gynecologic oncology 2002;84(2):353-4.
2002: Tarek Mekhail; Maurie Markman
Acanthosis nigricans with endometrial carcinoma: case report and review of the literature.
Gynecologic oncology 2002;84(2):332-4.
2002: Maurie Markman
Supportive care.
Cancer chemotherapy and biological response modifiers 2002;20():627-32.
2001: Maurie Markman; A Kennedy; J Kim
Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy.
Gynecologic oncology 2001;83(3):593-5.
2001: Simon A Smith; WE Richards; K Caito; Parviz Hanjani; Maurie Markman; Koen DeGeest; Holly H Gallion
BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
Gynecologic oncology 2001;83(3):586-92.
2001: Maurie Markman
Interactions between academic oncology and alternative/complementary/integrative medicine: complex but necessary.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18 Suppl):52S-53S.
2001: Kristine Zanotti; Lisa A Rybicki; Alexander W Kennedy; Jerome Belinson; Kenneth D Webster; Barbara Kulp; Gertrude Peterson; Maurie Markman
Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(12):3126-9.
2001: Maurie Markman
Prolonged symptom-free survival in a patient with persistent primary peritoneal carcinoma and a rising CA-125: a note of caution.
Gynecologic oncology 2001;81(3):509-11.
2001: Maurie Markman
Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer.
Critical reviews in oncology/hematology 2001;38(3):171-5.
2001: J Rohl; David M Kushner; Maurie Markman
Chronic administration of single-agent paclitaxel in gynecologic malignancies.
Gynecologic oncology 2001;81(2):201-5.
2001: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):1901-5.
2001: Maurie Markman; Brian N Bundy; D S Alberts; Jeffrey M Fowler; D L Clark-Pearson; L F Carson; S Wadler; J Sickel
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1001-7.
2001: Maurie Markman
Supportive care.
Cancer chemotherapy and biological response modifiers 2001;19():691-9.
2001: Kristine Zanotti; Maurie Markman
Prevention and management of antineoplastic-induced hypersensitivity reactions.
Drug safety : an international journal of medical toxicology and drug experience 2001;24(10):767-79.
2001: Maurie Markman
Intraperitoneal drug delivery of antineoplastics.
Drugs 2001;61(8):1057-65.
2001: Maurie Markman
Is there a role for intraperitoneal chemotherapy in the management of ovarian cancer?
Oncology (Williston Park, N.Y.) 2001;15(1):93-8; discussion 103-5.
2001: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies.
Journal of cancer research and clinical oncology 2001;127(1):55-8.
2000: Maurie Markman
Treatment of ovarian cancers not of epithelial origin.
Cleveland Clinic journal of medicine 2000;67(11):839-42.
2000: Kristine Zanotti; Jerome Belinson; Alexander W Kennedy; Kenneth D Webster; Maurie Markman
Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
Gynecologic oncology 2000;79(2):211-5.
2000: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
Gynecologic oncology 2000;79(1):116-9.
2000: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Gynecologic oncology 2000;78(3 Pt 1):369-72.
2000: Maurie Markman
Limits to the "benefits" from our oncologic interventions: a case report.
Gynecologic oncology 2000;78(2):261-2.
2000: David M Kushner; Kenneth D Webster; Jerome Belinson; Lisa A Rybicki; Alexander W Kennedy; Maurie Markman
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Gynecologic oncology 2000;78(2):221-7.
2000: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
Gynecologic oncology 2000;78(1):43-6.
2000: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia.
Journal of cancer research and clinical oncology 2000;126(5):298-300.
2000: Maurie Markman; Alexander Kennedy; K Webster; G Peterson; Barbara Kulp; Jerome Belinson
Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results.
Gynecologic oncology 2000;77(2):321-2.
2000: Maurie Markman
The genetics, screening, and treatment of epithelial ovarian cancer: an update.
Cleveland Clinic journal of medicine 2000;67(4):294-8.
2000: Maurie Markman; M A Bookman
Second-line treatment of ovarian cancer.
The oncologist 2000;5(1):26-35.
2000: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):102-5.
1999: Maurie Markman; John A Blessing; Koen DeGeest; M Morgan; Katherine Y Look; T J Herzog; Peter G Rose
Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
Gynecologic oncology 1999;75(3):444-6.
1999: D Abramovich; Maurie Markman; Alexander Kennedy; K Webster; Jerome Belinson
Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma.
Journal of cancer research and clinical oncology 1999;125(12):697-8.
1999: J S Berek; Maurie Markman; B Stonebraker; Samuel S Lentz; M D Adelson; Koen DeGeest; D Moore
Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
Gynecologic oncology 1999;75(1):10-4.
1999: Maurie Markman
Intraperitoneal chemotherapy.
Critical reviews in oncology/hematology 1999;31(3):239-46.
1999: Kristine Zanotti; Jerome Belinson; Alexander W Kennedy; Kenneth D Webster; Maurie Markman
The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
Gynecologic oncology 1999;74(2):272-7.
1999: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Journal of cancer research and clinical oncology 1999;125(7):427-9.
1999: Jonathan S Berek; Maurie Markman; John A Blessing; P R Kucera; B E Nelson; Barrie Anderson; Parviz Hanjani
Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
Gynecologic oncology 1999;74(1):48-52.
1999: Maurie Markman; A Kennedy; K Webster; Barbara Kulp; G Peterson; J Belinson
Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer.
Gynecologic oncology 1999;73(3):422-3.
1999: Amreen Husain; Paul Sabbatini; David Spriggs; DW Fennelly; Carol Aghajanian; Richard R Barakat; J Curtin; Venkatraman E Seshan; William J Hoskins; Maurie Markman
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
Gynecologic oncology 1999;73(1):96-101.
1999: Maurie Markman
Supportive care.
Cancer chemotherapy and biological response modifiers 1999;18():590-600.
1999: Maurie Markman
Diagnosis and management of superior vena cava syndrome.
Cleveland Clinic journal of medicine 1999;66(1):59-61.
1999: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias.
Gynecologic oncology 1999;72(1):100-1.
1998: Alexander W Kennedy; Maurie Markman; Kenneth D Webster; Barbara Kulp; Gertrude Peterson; Lisa A Rybicki; Jerome Belinson
Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum.
Gynecologic oncology 1998;71(2):288-90.
1998: Maurie Markman
Why should cancer patients participate in clinical trials?
Cleveland Clinic journal of medicine 1998;65(9):497-9.
1998: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Gynecologic oncology 1998;71(1):113-5.
1998: Yan Xu; Z Shen; D W Wiper; M Wu; Richard E Morton; Paul Elson; Alexander W Kennedy; Jerome Belinson; Maurie Markman; Graham Casey
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
JAMA : the journal of the American Medical Association 1998;280(8):719-23.
1998: Maurie Markman; A Kennedy; G Sutton; J Hurteau; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Gynecologic oncology 1998;70(2):272-4.
1998: Maurie Markman; Mark F Brady; Nick M Spirtos; Parviz Hanjani; S C Rubin
Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2620-4.
1998: Maurie Markman; John A Blessing; D Moore; H Ball; Samuel S Lentz
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Gynecologic oncology 1998;69(3):226-9.
1998: Maurie Markman
Intraperitoneal therapy of ovarian cancer.
Seminars in oncology 1998;25(3):356-60.
1998: Maurie Markman; Peter G Rose; E Jones; Ira R Horowitz; A Kennedy; Kenneth Webster; Jerome Belinson; Nancy Fusco; L Fluellen; Barbara Kulp; Gertrude Peterson; William P McGuire
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1849-51.
1998: Maurie Markman
The high cost of terminal care: balancing conflicting goals.
Cleveland Clinic journal of medicine 1998;65(4):219-21.
1998: Maurie Markman
Cancer and the mind: separating fact from fiction.
Cleveland Clinic journal of medicine 1998;65(2):107-9.
1998: Maurie Markman
Thirty-ninth annual meeting of the American Society of Hematology. 5-9 December 1997, San Diego.
Journal of cancer research and clinical oncology 1998;124(7):407-8.
1998: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma.
Journal of cancer research and clinical oncology 1998;124(6):326-8.
1997: F Shapiro; J Schneider; Maurie Markman; B S Reichman; Venkatraman E Seshan; Richard R Barakat; Lois Almadrones; David Spriggs
High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Gynecologic oncology 1997;67(1):39-45.
1997: Maurie Markman
Assessing and minimizing reproductive risks of cancer chemotherapy.
Cleveland Clinic journal of medicine 1997;64(9):465-7.
1997: Maurie Markman; A Kennedy; K Webster; Barbara Kulp; G Peterson; J Belinson
Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
Gynecologic oncology 1997;65(3):434-6.
1997: Maurie Markman
Ethical issues in clinical trials in oncology.
Cleveland Clinic journal of medicine 1997;64(5):275-7.
1997: Maurie Markman
Calculating cancer risk: it is harder than it seems.
Cleveland Clinic journal of medicine 1997;64(4):220-1.
1997: Maurie Markman; David M Peereboom
From serendipity to design: the evolution of drug development in oncology.
Cleveland Clinic journal of medicine 1997;64(3):155-63.
1997: Maurie Markman
Topotecan: an important new drug in the management of ovarian cancer.
Seminars in oncology 1997;24(1 Suppl 5):S5-1.
1997: Maurie Markman
The dilemma of evaluating and treating cancer of unknown primary site.
Cleveland Clinic journal of medicine 1997;64(2):73-5.
1997: Maurie Markman
Supportive care.
Cancer chemotherapy and biological response modifiers 1997;17():672-83.
1997: Maurie Markman
Thirty-eighth Annual Meeting of the American Society of Hematology.
Journal of cancer research and clinical oncology 1997;123(4):235-6.
1997: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis.
Journal of cancer research and clinical oncology 1997;123(4):224-6.
1997: Maurie Markman
When and how to use serum tumor markers in clinical practice.
Cleveland Clinic journal of medicine 1997;64(1):27-9.
1996: E Connelly; Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.
Gynecologic oncology 1996;62(2):166-8.
1996: Maurie Markman; K A Iseminger; K D Hatch; William T Creasman; W Barnes; B Dubeshter
Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.
Gynecologic oncology 1996;62(1):4-6.
1996: Maurie Markman; H Homesley; D A Norberts; J Schink; FOUAD ABBAS; A Miller; J Soper; N Teng; N Hammond; F Muggia; M Israel; T Sweatman
Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies.
Gynecologic oncology 1996;61(1):90-3.
1996: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasone.
Gynecologic oncology 1996;60(3):435-7.
1996: Maurie Markman; T Hakes; Richard R Barakat; J Curtin; Lois Almadrones; William J Hoskins
Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):796-9.
1996: Maurie Markman
Eighty-seventh annual meeting of the American Association for Cancer Research. Washington, D,C., 20-24 April 1996.
Journal of cancer research and clinical oncology 1996;122(9):568-9.
1996: Maurie Markman
Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies?
Cancer investigation 1996;14(5):498-500.
1996: Maurie Markman
Supportive care.
Cancer chemotherapy and biological response modifiers 1996;16():644-54.
1995: P Francis; eric rowinsky; J Schneider; T Hakes; William J Hoskins; Maurie Markman
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2961-7.
1995: Maurie Markman
Intraperitoneal paclitaxel in the management of ovarian cancer.
Seminars in oncology 1995;22(5 Suppl 12):86-7.
1995: Maurie Markman
Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
Seminars in oncology 1995;22(3 Suppl 6):88-9.
1995: Maurie Markman; P Francis; eric rowinsky; William J Hoskins
Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer?
Seminars in oncology 1995;22(3 Suppl 6):84-7.
1995: Maurie Markman
Surgery for support and palliation in patients with malignant disease.
Seminars in oncology 1995;22(2 Suppl 3):91-4.
1995: Maurie Markman
The use of chemotherapy as palliative treatment for patients with advanced ovarian cancer.
Seminars in oncology 1995;22(2 Suppl 3):25-9.
1995: Maurie Markman
26th annual meeting of the Society of Gynecologic Oncologists. San Francisco, 18-22 February 1995.
Journal of cancer research and clinical oncology 1995;121(5):315-6.
1995: Maurie Markman
36th annual meeting of the American Society of Hematology. Nashville, 2-6 December 1994.
Journal of cancer research and clinical oncology 1995;121(5):313-4.
1995: Maurie Markman
The objective clinical scientist versus the advocate: a complex ethical and political dilemma facing cancer investigators and the public.
Cancer investigation 1995;13(3):324-6.
1995: Maurie Markman
Thirty-first annual meeting of the American Society of Clinical Oncology. Los Angeles, California, 20-23 May 1995.
Journal of cancer research and clinical oncology 1995;121(8):490-1.
1995: Maurie Markman
86th annual meeting of the American Association for Cancer Research. Toronto, Canada, March 18-22, 1995.
Journal of cancer research and clinical oncology 1995;121(7):439-40.
1995: Maurie Markman
Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies?
Cancer investigation 1995;13(6):625-8.
1994: Maurie Markman
Follow-up of the asymptomatic patient with ovarian cancer.
Gynecologic oncology 1994;55(3 Pt 2):S134-7.
1994: Maurie Markman
Realistic goals of cancer therapy: effective and humane care.
Cleveland Clinic journal of medicine 1994;61(6):468-72.
1994: Maurie Markman
Introduction: treatment of malignancies poorly responsive to currently available antineoplastic therapy.
Seminars in oncology 1994;21(4 Suppl 7):1-2.
1994: Valerie W Rusch; Leonard B Saltz; Venkatraman E Seshan; Robert J Ginsberg; P McCormack; M Burt; Maurie Markman; David P Kelsen
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(6):1156-63.
1994: Maurie Markman
Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.
Seminars in oncology 1994;21(2 Suppl 2):17-9; quiz 20, 58.
1994: Maurie Markman
Common complications and emergencies associated with cancer and its therapy.
Cleveland Clinic journal of medicine 1994;61(2):105-14; quiz 162.
1994: Maurie Markman
Fourth biennial meeting of the International Gynecologic Cancer Society, Stockholm 1993.
Journal of cancer research and clinical oncology 1994;120(4):248-9.
1994: Maurie Markman
Thirty-fifth annual meeting of the American Society of Hematology, St. Louis, Missouri, December 1993.
Journal of cancer research and clinical oncology 1994;120(7):437-8.
1994: Maurie Markman
Ovarian cancer update: management challenges and advances.
Cleveland Clinic journal of medicine 1994;61(1):51-8; quiz 80-2.
1994: Maurie Markman
Twenty-fifth meeting of the Society of Gynecologic Oncologists. Orlando, Florida, February 1994.
Journal of cancer research and clinical oncology 1994;120(9):562-3.
1994: Maurie Markman
When regulatory requirements conflict with ethical study design: the case of oral ondansetron.
Cancer investigation 1994;12(6):654-6.
1994: Maurie Markman; P Francis; eric rowinsky; T Hakes; B Reichman; W Jones; J L Lewis; S Rubin; J Curtin; Richard R Barakat
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 6():S55-8.
1994: Maurie Markman
30th annual meeting of the American Society of Clinical Oncology. Dallas, Texas, May 1994.
Journal of cancer research and clinical oncology 1994;120(12):745-6.
1994: Maurie Markman
85th annual meeting of the American Association for Cancer Research. San Francisco, California, April 1994.
Journal of cancer research and clinical oncology 1994;120(12):743-4.
1994: Maurie Markman
Supportive care.
Cancer chemotherapy and biological response modifiers 1994;15():665-74.
1993: Maurie Markman
Salvage therapy in ovarian cancer: is there a role for intraperitoneal drug delivery?
Gynecologic oncology 1993;51(1):86-9.
1993: Maurie Markman; John A Blessing; F Major; A Manetta
Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
Gynecologic oncology 1993;50(2):191-5.
1993: B Reichman; Maurie Markman; T Hakes; S Rubin; W Jones; J Curtin; Richard R Barakat; Lois Almadrones; J L Lewis; William J Hoskins
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.
Gynecologic oncology 1993;50(1):30-3.
1993: Maurie Markman; B Reichman; T Hakes; S Rubin; J L Lewis; W Jones; Richard R Barakat; J Curtin; Lois Almadrones; William J Hoskins
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
Gynecologic oncology 1993;50(1):100-4.
1993: Maurie Markman
Surgeon's skill key to ovarian cancer management.
Cleveland Clinic journal of medicine 1993;60(3):183-4.
1993: Maurie Markman; J L Lewis; Patricia E Saigo; T Hakes; S Rubin; W Jones; B Reichman; J Curtin; Richard R Barakat; Lois Almadrones
Impact of age on survival of patients with ovarian cancer.
Gynecologic oncology 1993;49(2):236-9.
1993: Maurie Markman; T Hakes; B Reichman; S Rubin; J Curtin; Richard R Barakat; W Jones; J L Lewis; Lois Almadrones; William J Hoskins
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment.
Gynecologic oncology 1993;49(2):185-9.
1993: Maurie Markman; B Reichman; T Hakes; S Rubin; W Jones; J L Lewis; Richard R Barakat; J Curtin; Lois Almadrones; William J Hoskins
The use of recombinant human erythropoietin to prevent carboplatin-induced anemia.
Gynecologic oncology 1993;49(2):172-6.
1993: Maurie Markman; D Alberts; S Rubin; T Hakes; J L Lewis; B Reichman; W Jones; J Curtin; Richard R Barakat; F Brodar
Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery.
Gynecologic oncology 1993;48(2):185-8.
1993: Maurie Markman
Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity.
Critical reviews in oncology/hematology 1993;14(1):15-28.
1993: Maurie Markman
Report from the 28th Annual Meeting of the American Society of Clinical Oncology. 17-19 May 1992.
Journal of cancer research and clinical oncology 1993;119(6):369-70.
1993: Maurie Markman; L C DeMarco; M Birkhofer; D Budman; T Hakes; B Reichman; S Rubin; W Jones; Richard R Barakat; J Curtin
Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy.
Journal of cancer research and clinical oncology 1993;119(4):234-6.
1993: Maurie Markman
Report from the 24th annual meeting of the Society of Gynecologic Oncologists, February 7-10, 1993.
Journal of cancer research and clinical oncology 1993;119(12):759-60.
1993: P Francis; Maurie Markman; T Hakes; B Reichman; S Rubin; W Jones; J L Lewis; J Curtin; Richard R Barakat; M Phillips
Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicity.
Journal of cancer research and clinical oncology 1993;119(6):360-2.
1993: Maurie Markman
Report from the 34th annual meeting of the American Society of Hematology, December 4-8, 1992.
Journal of cancer research and clinical oncology 1993;119(11):695-6.
1993: Maurie Markman
Salvage intraperitoneal chemotherapy for ovarian cancer: a possible role for mitoxantrone?
European journal of cancer (Oxford, England : 1990) 1993;29A(9):1225-6.
1993: Maurie Markman
Supportive care.
Cancer chemotherapy and biological response modifiers 1993;14():641-50.
1993: Maurie Markman
Report from the 29th annual meeting of the American Society of Clinical Oncology, 16-18 May 1993, Orlando, Florida.
Journal of cancer research and clinical oncology 1993;120(1-2):119-20.
1993: Maurie Markman
Report from the Second National Cancer Institute Workshop on Taxol and Taxus. 23-24 September 1992.
Journal of cancer research and clinical oncology 1993;119(7):439-40.
1992: Maurie Markman; T Hakes; B Reichman; Richard R Barakat; J Curtin; W Jones; J L Lewis; S Rubin; Lois Almadrones; William J Hoskins
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?
Seminars in oncology 1992;19(6 Suppl 14):25-7.
1992: Maurie Markman; B Reichman; T Hakes; S Rubin; W Jones; J L Lewis; Richard R Barakat; J Curtin; Lois Almadrones; William J Hoskins
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer.
Gynecologic oncology 1992;47(3):353-7.
1992: Maurie Markman
Systemic therapy for gynecologic cancer.
Current opinion in oncology 1992;4(5):939-45.
1992: Richard R Barakat; S C Rubin; G Wong; Patricia E Saigo; Maurie Markman; William J Hoskins
Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases.
Obstetrics and gynecology 1992;80(4):660-4.
1992: Maurie Markman; B Reichman; T Hakes; J L Lewis; W Jones; S Rubin; Richard R Barakat; J Curtin; Lois Almadrones; William J Hoskins
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(9):1479-84.
1992: Maurie Markman; eric rowinsky; T Hakes; B Reichman; W Jones; J L Lewis; S Rubin; J Curtin; Richard R Barakat; M Phillips
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(9):1485-91.
1992: T B Hakes; E Chalas; William J Hoskins; W B Jones; Maurie Markman; S C Rubin; D Chapman; Lois Almadrones; J L Lewis
Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
Gynecologic oncology 1992;45(3):284-9.
1992: Valerie W Rusch; D Niedzwiecki; Y Tao; C Menendez-Botet; Ann M Dnistrian; David P Kelsen; Leonard B Saltz; Maurie Markman
Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(6):1001-6.
1992: Maurie Markman; J S Berek; J A Blessing; W P McGuire; J Bell; Howard D Homesley
Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.
Gynecologic oncology 1992;45(1):3-8.
1992: Maurie Markman; T Hakes; B Reichman; J L Lewis; S Rubin; W Jones; Lois Almadrones; F Pizzuto; William J Hoskins
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(2):243-8.
1992: Maurie Markman; W Jones; J L Lewis; S Rubin; T Hakes; B Reichman; Richard R Barakat; J Curtin; Lois Almadrones; William J Hoskins
Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy.
Journal of cancer research and clinical oncology 1992;118(2):163-5.
1992: Maurie Markman; David P Kelsen
Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma.
Journal of cancer research and clinical oncology 1992;118(7):547-50.
1992: Maurie Markman; B Reichman; T Hakes; J Curtin; Richard R Barakat; S Rubin; W Jones; J L Lewis; Lois Almadrones; William J Hoskins
Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapy.
Journal of cancer research and clinical oncology 1992;118(5):391-4.
1992: Maurie Markman; B Reichman; T Hakes; Richard R Barakat; J Curtin; S Rubin; W Jones; J L Lewis; Lois Almadrones; William J Hoskins
Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate.
Journal of cancer research and clinical oncology 1992;118(3):235-7.
1992: Maurie Markman; T Hakes; B Reichman; J Curtin; Richard R Barakat; S Rubin; W Jones; J L Lewis; Lois Almadrones; William J Hoskins
Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer.
Journal of cancer research and clinical oncology 1992;119(1):55-7.
1992: Maurie Markman
Ethical difficulties with randomized clinical trials involving cancer patients: examples from the field of gynecologic oncology.
The Journal of clinical ethics 1992;3(3):193-5.
1991: B Reichman; Maurie Markman; T Hakes; A Budnick; S Rubin; W Jones; Lois Almadrones; J L Lewis; William J Hoskins
Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy.
Gynecologic oncology 1991;43(2):159-63.
1991: Maurie Markman
Taxol: an important new drug in the management of epithelial ovarian cancer.
The Yale journal of biology and medicine 1991;64(6):583-90.
1991: Maurie Markman; B Reichman; T Hakes; W Jones; J L Lewis; S Rubin; Lois Almadrones; William J Hoskins
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(10):1801-5.
1991: Richard R Barakat; S C Rubin; Patricia E Saigo; D Chapman; J L Lewis; W B Jones; T B Hakes; Maurie Markman; B Reichman; William J Hoskins
Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube.
Gynecologic oncology 1991;42(2):156-60.
1991: S C Rubin; William J Hoskins; Patricia E Saigo; D Chapman; T B Hakes; Maurie Markman; B Reichman; Lois Almadrones; J L Lewis
Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy.
Gynecologic oncology 1991;42(2):137-41.
1991: Maurie Markman
Intraperitoneal chemotherapy.
Seminars in oncology 1991;18(3):248-54.
1991: Maurie Markman; T Hakes; B Reichman; J L Lewis; S Rubin; W Jones; Lois Almadrones; William J Hoskins
Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(6):978-82.
1991: Maurie Markman; R Rothman; T Hakes; B Reichman; J L Lewis; S Rubin; W Jones; Lois Almadrones; William J Hoskins
Late effects of cisplatin-based chemotherapy on renal function in patients with ovarian carcinoma.
Gynecologic oncology 1991;41(3):217-9.
1991: J A Smith-Rogers; W P Tong; M E Duafala; Maurie Markman; Joseph R Bertino
High-performance liquid chromatographic method for the simultaneous measurement of floxuridine and fluorouracil in human body fluids.
Journal of chromatography 1991;566(1):147-54.
1991: S A Davidson; S C Rubin; Maurie Markman; W B Jones; T B Hakes; B Reichman; Lois Almadrones; D Chapman; J L Lewis; William J Hoskins
Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system.
Gynecologic oncology 1991;41(2):101-6.
1991: Maurie Markman; R Rothman; T Hakes; B Reichman; William J Hoskins; S Rubin; W Jones; Lois Almadrones; J L Lewis
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(3):389-93.
1991: Maurie Markman; T Hakes; B Reichman; William J Hoskins; S Rubin; W Jones; Lois Almadrones; E L Yordan; J Eriksson; J L Lewis
Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(2):204-10.
1991: Maurie Markman; R D'Acquisto; N Iannotti; Mark G Kris; T Hakes; Dean F Bajorin; George J Bosl; B Reichman; E Casper; G Magill
Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate.
Journal of cancer research and clinical oncology 1991;117(2):151-5.
1991: JP Curtin; William J Hoskins; S C Rubin; W B Jones; T B Hakes; Maurie Markman; B Reichman; Lois Almadrones; J L Lewis
Chemotherapy-induced neutropenia and fever in patients receiving cisplatin-based chemotherapy for ovarian malignancy.
Gynecologic oncology 1991;40(1):17-20.
1990: L W Ng; S C Rubin; William J Hoskins; W B Jones; T B Hakes; Maurie Markman; B Reichman; Lois Almadrones; J L Lewis
Aggressive chemosurgical debulking in patients with advanced ovarian cancer.
Gynecologic oncology 1990;38(3):358-63.
1990: S C Rubin; CL Finstad; William J Hoskins; Patricia E Saigo; D M Provencher; Mark G Federici; T B Hakes; Maurie Markman; B S Reichman; Kenneth O Lloyd
Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance.
American journal of obstetrics and gynecology 1990;163(1 Pt 1):69-73.
1990: Maurie Markman; M George; T Hakes; B Reichman; William J Hoskins; S Rubin; W Jones; Lois Almadrones; J L Lewis
Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(1):146-50.
1989: B Reichman; Maurie Markman; T Hakes; William J Hoskins; S Rubin; W Jones; Lois Almadrones; M Ochoa; D Chapman; Patricia E Saigo
Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(9):1327-32.
1989: William J Hoskins; S C Rubin; E Dulaney; D Chapman; Lois Almadrones; Patricia E Saigo; Maurie Markman; T Hakes; B Reichman; W B Jones
Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma.
Gynecologic oncology 1989;34(3):365-71.
1989: S C Rubin; William J Hoskins; Maurie Markman; Mark G Federici; Kenneth O Lloyd; J L Lewis
Synergistic activity of tumor necrosis factor and interferon in a nude mouse model of human ovarian cancer.
Gynecologic oncology 1989;34(3):353-6.
1989: Maurie Markman
Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
Seminars in oncology 1989;16(4 Suppl 6):79-82.
1989: Maurie Markman; T Hakes; B Reichman; William J Hoskins; S Rubin; W Jones; L Almadones; J L Lewis
Intraperitoneal therapy in the management of ovarian carcinoma.
The Yale journal of biology and medicine 1989;62(4):393-403.
1989: J A Smith; A Morris; M E Duafala; Joseph R Bertino; Maurie Markman; M Kleinberg
Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration.
American journal of hospital pharmacy 1989;46(5):985-9.
1989: S C Rubin; William J Hoskins; Maurie Markman; T Hakes; J L Lewis
Long-term access to the peritoneal cavity in ovarian cancer patients.
Gynecologic oncology 1989;33(1):46-8.
1989: S C Rubin; William J Hoskins; T B Hakes; Maurie Markman; B S Reichman; D Chapman; J L Lewis
Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.
American journal of obstetrics and gynecology 1989;160(3):667-71.
1989: Maurie Markman; B Reichman; T Hakes; William J Hoskins; S Rubin; W Jones; J L Lewis
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Acta medica Austriaca 1989;16(3-4):65-7.
1989: Maurie Markman
Issues involved in providing quality and optimal care for the cancer patient in the era of cost containment.
Cancer investigation 1989;7(4):395-8.
1988: S C Rubin; William J Hoskins; T B Hakes; Maurie Markman; J M Cain; J L Lewis
Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors.
American journal of obstetrics and gynecology 1988;159(5):1094-8.
1988: S C Rubin; E D Dulaney; Maurie Markman; William J Hoskins; Patricia E Saigo; J L Lewis
Peritoneal cytology as an indicator of disease in patients with residual ovarian carcinoma.
Obstetrics and gynecology 1988;71(6 Pt 1):851-3.
1988: Maurie Markman
An argument in support of cost-effectiveness analysis in oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(6):937-9.
1988: R D'Acquisto; Maurie Markman; T Hakes; S Rubin; William J Hoskins; J L Lewis
A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(4):689-95.
1988: B Reichman; Maurie Markman; T Hakes; Nancy Kemeny; David P Kelsen; William J Hoskins; S Rubin; J L Lewis
Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(1):158-62.
1987: Maurie Markman
Intraperitoneal chemotherapy as treatment of ovarian carcinoma: why, how, and when?
Obstetrical & gynecological survey 1987;42(9):533-9.
1987: Maurie Markman
Current status of intracavitary chemotherapy.
Oncology (Williston Park, N.Y.) 1987;1(1):25-30.
1987: Maurie Markman
Intraperitoneal chemotherapy for ovarian carcinoma.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1987;41(8):420-4.
1987: Maurie Markman
Clinical cancer research, DNR orders, and medical economics: a complex interrelationship.
Cancer investigation 1987;5(3):237-9.